POL6326-009

An International, Phase 3, Muticenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer
Contact phone
Clinical Trials Office – 517.364.9400
Principal investigator
Gordan Srkalovic
Trial Category
Cancer
Trial SubCategory
Metastatic Breast